BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN BEGIN:VTIMEZONE TZID:GMT Standard Time BEGIN:STANDARD DTSTART:20251002T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=10 TZNAME:GMT Standard Time TZOFFSETFROM:+0100 TZOFFSETTO:+0000 END:STANDARD BEGIN:DAYLIGHT DTSTART:20250301T010000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=1;BYMINUTE=0;BYMONTH=3 TZNAME:GMT Daylight Time TZOFFSETFROM:+0000 TZOFFSETTO:+0100 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Time: \;14:00 &ndash\; 15:00 UK Time\nPresenter: \;Bie Verbist\n\nClick here to view the presentation slides.\n\nAbstract\n\nBroa d toxicology profiling takes traditionally place at the interface between discovery and development when a potential drug candidate is selected. How ever\, it would be both time- and cost-wise better if mechanism (target)-r elated toxicity and compound-chemistry related toxicity is addressed earli er\, when discussions on novel drug targets take place and compound series are identified and optimized. As the traditional in-vivo and in-vitro tox icity testing is rather low-throughput\, they can&rsquo\;t be used in thes e early stages of the drug discovery process. Therefore a paradigm shift i n toxicity testing needs to take place to move to high-throughput cell-bas ed assays to reveal key pathways and proteins linked with toxicity end poi nts. I will present some explorations and case studies where both transcri ptional profiling and imaging techniques are explored to flag early potent ial toxicity issues already during the drug development process where the findings could still influence the final candidate selection. \;\n\nAb out the Presenter: \;Bie Verbist\n\n\nBie Verbist studied medicinal ch emistry at KU Leuven\, Belgium and finished PhD in 2005 on the design and synthesis of potential &beta\;‐turn mimetics in the group of Prof.Dr.G.Hoo rnaert. Following this\, she started as a post-doc at Johnson &\; Johns on Pharmaceutical Research and Development in Beerse\, Belgium where she w as involved in the design\, synthesis and validation of new biological ent ities within the therapeutic areas pain and internal medicine\, for three years. Afterwards\, she went back to university to follow a one-year MaNaM a in statistical data analysis. In 2011\, after a short period of working as a scientific collaborator at Ghent University on qPCR data\, she starte d a second PhD to search for low-frequency variants in viral populations u sing Illumina deep sequencing technologies under supervision of Prof.Dr. O . Thas and in close collaboration with Johnson &\; Johnson Pharmaceutic al Research and Development in Beerse\, Belgium. In 2014\, Bie joined John son &\; Johnson as a Principal Biostatistician in the non-clinical stat istics department to support oncology projects within discovery with a foc us on omics data analysis. \;\n\nTo access the recording\, please visi t the Video-on-Demand Library. DTEND:20180220T150000Z DTSTAMP:20260721T160624Z DTSTART:20180220T140000Z LOCATION: SEQUENCE:0 SUMMARY:PSI Webinar: Integrating transcriptomics into early safety screenin g UID:RFCALITEM639202467843271021 X-ALT-DESC;FMTTYPE=text/html:Time: \;14:00 &ndash\; 15 :00 UK Time
\nPresenter: \;Bie Verbist
\n\nClick here to view the presentation slides.
\n
\nAbstract
\n
\n

Broad toxicology profiling takes trad itionally place at the interface between discovery and development when a potential drug candidate is selected. However\, it would be both time- and cost-wise better if mechanism (target)-related toxicity and compound-chem istry related toxicity is addressed earlier\, when discussions on novel dr ug targets take place and compound series are identified and optimized. As the traditional in-vivo and in-vitro toxicity testing is rather low-throu ghput\, they can&rsquo\;t be used in these early stages of the drug discov ery process. Therefore a paradigm shift in toxicity testing needs to take place to move to high-throughput cell-based assays to reveal key pathways and proteins linked with toxicity end points. I will present some explorat ions and case studies where both transcriptional profiling and imaging tec hniques are explored to flag early potential toxicity issues already durin g the drug development process where the findings could still influence th e final candidate selection. \;

\n
\nAbout the Present er: \;Bie Verbist
\n
\n\n

p si webinarBie Verbist studied medicinal chemistry at KU Leuven\, Belgium and finished PhD in 2005 on the design and synthesis of potential &beta\;‐turn mimetic s in the group of Prof.Dr.G.Hoornaert. Following this\, she started as a p ost-doc at Johnson &\; Johnson Pharmaceutical Research and Development in Beerse\, Belgium where she was involved in the design\, synthesis and v alidation of new biological entities within the therapeutic areas pain and internal medicine\, for three years. Afterwards\, she went back to univer sity to follow a one-year MaNaMa in statistical data analysis. In 2011\, a fter a short period of working as a scientific collaborator at Ghent Unive rsity on qPCR data\, she started a second PhD to search for low-frequency variants in viral populations using Illumina deep sequencing technologies under supervision of Prof.Dr. O. Thas and in close collaboration with John son &\; Johnson Pharmaceutical Research and Development in Beerse\, Bel gium. In 2014\, Bie joined Johnson &\; Johnson as a Principal Biostatis tician in the non-clinical statistics department to support oncology proje cts within discovery with a focus on omics data analysis. \;

\n\nTo access the recording\, please visit the Video-on-Demand Library. END:VEVENT END:VCALENDAR